News & Updates
Filter by Specialty:
Show Multimedia Only

Sacituzumab govitecan makes case as third-line therapy in mTNBC
05 Feb 2024
Third-line treatment with sacituzumab govitecan works better than the physician’s treatment of choice in metastatic triple-negative breast cancer (mTNBC), an invasive histologic subtype with a poor prognosis and rapid progression, as shown in a recent study.
Sacituzumab govitecan makes case as third-line therapy in mTNBC
05 Feb 2024
Erdafitinib prevents recurrence in high-risk NMIBC
04 Feb 2024
byStephen Padilla
Recurrence-free survival (RFS) is significantly longer with erdafitinib treatment than with intravesical chemotherapy in patients with papillary-only, high-risk nonmuscle-invasive bladder cancer (NMIBC) who had disease recurrence after bacillus Calmette–Guérin (BCG) therapy and were ineligible for radical cystectomy, according to a study.